Epidural Spinal Cord Stimulation for Neuropathic Pain: Algology Unit in Bagcilar Training and Research Hospital Data Collection and Analysis

Abstract
Spinal cord stimulation (SCS) is a technique used worldwide to treat several types of chronic neuropathic pain refractory to any conservative treatment.

Objective: The aim of this data collection is to enforce evidence of SCS effectiveness in treating neuropathic chronic pain and the very low percentage of undesired side effects of complications reported in our case series suggests that all implants should be performed by similarly well-trained and experienced professionals.

Methods: Data collection from algology unit in Bagcilar Training and Research Hospital started 3 years ago. Two different types electrodes (octet and lamitrode) were used. 18 patients were underwent permanent implant after training period.

Results: Most of the patients had predominant pain to lower limbs. Significant reduction in pain, as measured by variation in visual analogue scale (VAS) score, was observed at least 2 year after implantation. All the patients’ VAS scores statistically significant lower than baseline VAS scores 24 months after implantation.

Discussion: We discuss about three aspects of SCS implant: pain reduction, quality of life and complication. No statistically significant differences were found between lower limbs pain group and axial pain group. We analysed quality of life outcomes using three rating scales: ODI, EQ5D and SF36 questionnaire and we also tested patients with Hamilton’s scale for depression. In our analysis, we also found a general improvement of quality of life in terms of ODI, EQ5D and SF36 questionnaires. ODI improvement after 12 and 24 months was greater than 50% from baseline in 100% of patients. Our overall complications rate (4.5%) is comparable or lower than that reported in the main literature.

Conclusion: Our results enforce the evidence of efficacy of SCS therapy in terms of pain reduction, patient satisfaction and quality of life, according to previously published studies.

Keywords: Neuropathic pain; Spinal cord stimulation; Pharmacological therapy; Hyperalgesia

Introduction
Neuropathic pain is a chronic condition, challenging to treat and deeply correlated with psychological aspect: it can be codetermined by emotional and behavioural factors, and it can play an important role in determining depression or in decreasing quality of life. Spinal cord stimulation (SCS) is a therapeutic option in patients with chronic/neuropathic pain with different aetiologies (i.e. failed back surgery syndrome (FBSS), chronic spine pathologies and neuropathic diseases) [1-5] not eligible for surgery and refractory to any pharmacological and other conservative treatment [6].
SCS is theoretically based on the Gate Control Theory developed by Melzack and Wall [7], which explains physiopathology of such conditions as hyperalgesia, painful anaesthesia and spontaneous pain. The loss of large peripheral nerve fibres after a nerve injury produced a drop in the inhibition on the slow C-fibres inputs causing the open-gate condition responsible of these types of pain.

SCS has demonstrated to be more effective on neuropathic pain compared with nociceptive pain [6]. The best result of this technique were initially observed in patients affected by post-herpetic neuralgia and vasculopathic pain, with good pain relief in more than 60% of patients [5]. The role of SCS in treating low-back pain was debated in the past because of the reduction of pain control at long-term follow-up [2,5]. Some authors demonstrated that SCS associated with standard pharmacological therapy could reduce chronic pain more than common pharmacological therapies used alone and it could improve quality of life and patients return to their own occupation [8,9].

Various authors identified the important role of psychological factors on pain modulation and on effectiveness of SCS [5,7,10-12]. Thanks to technological improvements of both leads and implantable pulse generators (IPG), and the more accurate selection of patients, SCS has gained increasing reliability in the armamentarium of surgical and analgesic techniques to control pain when conservative and other surgical treatments failed. FBSS is presently the main indication for SCS, followed by complex regional pain syndrome (CRPS), intractable angina pectoris and pain due to peripheral vascular disease [13-15]. Further indications comprise painful conditions related to peripheral nerve chronic diseases, in which this technique should be preferred to more invasive and ablative treatments [1,4,5].

Usually patients are submitted to psychological evaluation and quality-of-life assessment before undergoing the trial period for 15-21 days [10].

According to currently available evidence, the role of SCS in FBSS is particularly demonstrated in those conditions with prevalent lower-limb pain [16], with best results in unilateral leg pain [5,8,17,18]. Some authors reported therapy-effectiveness and cost-effectiveness of SCS versus reoperation in FBSS, assuming the correct selection of patients and the importance of trial period. SCS is often used after all the surgical procedures available of spine pathologies, with possible reduction of its potential therapeutic role [19-21]. Furthermore, prevalent back pain has a reported lower response to SCS, which might be related to the nociceptive component of pain in this group of patient [6,19,20].

The aim of this data collection is to enforce evidence of SCS effectiveness in treating neuropathic chronic pain.

**Materials and Methods**

Between September 2012 and September 2014, 22 subjects were assessed in algology polyclinic in Bağcılar Training and Research Hospital. Each patient gave written informed consent for data collection and analysis.

All patients eligible to SCS therapy were considered for analysis. We analysed the characteristics of patients in terms of base-line features, implant indications, pain distribution, duration of pain, type of implanted device and type of surgical procedure.

Patients who underwent the permanent implant were evaluated after 6,12,18 and 24 months. In the present paper, we analysed SCS outcomes after 24 months.

### Pre-implant data collection

Each patient was submitted to a pre-implant data collection form to evaluate the features of chronic pain. Within the total population of 22 patients, 11 were women (50%) and 11 men (50%). The mean age of patients at the moment of permanent implant was 60.50 ± 14.98 years old (range, 32-85) and the mean pain duration was 24 months (range, 12-48 months).

Prevalent pain was localized to the lower limbs in 12 patients (75%), the lower back (also defined as ‘axial pain) in 8 patients (49%) and the upper limbs in the remaining 2 patient (Table 1). The prevalent visual analogue scale (VAS) value is determined as the greater baseline value between the axial VAS value and lower-limb VAS value for each patient.

The mean onset VAS value was 9 ± 1.27 for lower limb pain and 8.75 ± 1.39 for axial pain.

Pain was associated with one or more accompanying symptoms in 10 patients (63.4%), including numbness (n=5, 50%), weakness (n=4, 40%) and other symptoms (n= 5, 50%)

Before implant, we asked the patients to list previous non-invasive therapies they had undergone for neuropathic pain, and currently ongoing pharmacological therapies. All patients (100%) had ongoing both pharmacological therapy and non-pharmacological therapy (Table 2).

Patients’ weight and the corresponding body mass index (BMI) were analysed, showing a mean weight 76.4 kg (range, 45-120 kg) and a mean BMI of 28 (range, 20-34). With respect to smoking habit, we found that all patients non-smokers. Prevalence of common disease, i.e. hypertension and diabetes, was comparable to the general population [21,22].

### Implant indications

Patients’ selection was done by each neurosurgeon during out patients clinic, following exclusion criteria reported in literature [6]:

<table>
<thead>
<tr>
<th>Painful area</th>
<th>Prevalent axial</th>
<th>Prevalent lower limbs</th>
<th>Prevalent upper limbs</th>
<th>Low back</th>
<th>Low back and one inferior extremity</th>
<th>Low back and both inferior extremities</th>
<th>One inferior extremities</th>
<th>Both inferior extremities</th>
<th>Other (Upper limbs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Painful area</td>
<td>9 (40.90%)</td>
<td>8 (36.36%)</td>
<td>1 (4.54%)</td>
<td>9 (40.90%)</td>
<td>2 (9.09%)</td>
<td>6 (27.27%)</td>
<td>3 (13.63%)</td>
<td>3 (13.63%)</td>
<td>1 (4.54%)</td>
</tr>
</tbody>
</table>
1. Complete lesions of the dorsal column (i.e. total paraplegia).
2. Presence of pathological conditions (i.e. multiple sclerosis) needs a magnetic resonance imaging (MRI) follow-up.
3. Patients with chronic pain who have not tried non-invasive therapeutic options, pharmacological and non-pharmacological (i.e. physiotherapy, TENS).
4. Patient with chronic pain associated with a pathological condition that could be surgically treated.
5. Coagulopathy or immunodeficiency disorders, which could interfere with neuromodulation procedures.
6. Major psychiatric disorders, drug or alcohol abuse, existing drug habituation problems, poor compliance or low/absent possibility to understand the therapy.
7. Cardiac pace-maker (PM) or implantable cardiac defibrillator (ICD).

The pathologies affecting our patients are summarized in Table 2.

All patients were suffering from neuropathic pain, localized to the lower limbs, lower back or both. In FBSS group (7 patients, 49%), 7 patients (49%) underwent multiple spine surgeries, 3 patients (19%) had single or multiple discectomies and 3 patients (22.72%) were subjected to instrumented spine surgery (Table 3).

Eight patients (50%) suffered for chronic neuropathic pain of different origin and never had any spine surgery.

### Table 2 Rates of primary pathologies and previous non-invasive treatments.

<table>
<thead>
<tr>
<th>Primary pathalogy</th>
<th>No. of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discectomy (Multiple surgery)</td>
<td>4 (18.18)</td>
</tr>
<tr>
<td>Laminectomy (Single surgery)</td>
<td>2 (9.09%)</td>
</tr>
<tr>
<td>Laminectomy (Multiple surgery)</td>
<td>2 (9.09%)</td>
</tr>
<tr>
<td>Lumbar fusion (Multiple surgery)</td>
<td>3 (13.63%)</td>
</tr>
<tr>
<td>Lumbar spine pathologies (Without previous surgery)</td>
<td>7 (31.81)</td>
</tr>
<tr>
<td><strong>Others</strong></td>
<td></td>
</tr>
<tr>
<td>Peripheral nerve injury</td>
<td>2 (9.09)</td>
</tr>
<tr>
<td>Vertebral/vertebral trauma</td>
<td>1 (4.54)</td>
</tr>
<tr>
<td>Limb amputation</td>
<td>1 (4.54)</td>
</tr>
<tr>
<td><strong>Previous non-invasive therapies</strong></td>
<td></td>
</tr>
<tr>
<td>Pharmacological therapies</td>
<td>22</td>
</tr>
<tr>
<td>Opioids</td>
<td>22</td>
</tr>
<tr>
<td>NSAIDS</td>
<td>22</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>22</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>22</td>
</tr>
<tr>
<td>Steroids</td>
<td>22</td>
</tr>
<tr>
<td>Other Drugs</td>
<td>22</td>
</tr>
<tr>
<td><strong>Non-pharmacological therapies</strong></td>
<td></td>
</tr>
<tr>
<td>Physiotherapy</td>
<td>22</td>
</tr>
<tr>
<td>TENS</td>
<td>22</td>
</tr>
<tr>
<td>Radicular block</td>
<td>22</td>
</tr>
<tr>
<td>Other therapies</td>
<td>22</td>
</tr>
</tbody>
</table>


### Technical notes

We used two types of epidural leads 1. (Medtronic, Mineapoli, MN, USA): percutaneous leads (Octet electrode lead) and St Jude Medical, USA); Percutaneous leads (8-electrode-S-series).

Percutaneous leads of Medtronic are inserted into the epidural space with a needle-guide and without opening the facia. 2. Percutaneous leads of S-series (Lamitrode) are inserted into the epidural space with a needle-guide by epiducer and without opening the facia. In both of the procedure both a lateral X-ray and A-P X-ray scan was used to control the spine level, (Electrode was placed to thoracolomer epidural space which entrance was L₂₃ intervertebral space and the tip of the electrode was middle of the T₈ vertebral body in the A-P X-ray) (Figures 1 and 2). The number and shape of leads were selected according to the extension of painful area.

### Table 3 Reduction of VAS, reported as median (minimum-maximum) (range) (Prevalent VAS score explained in Materials and methods) (Medium ± Min-Max).

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Baseline</th>
<th>6 months</th>
<th>P values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Axial VAS</td>
<td>10 (8-10)</td>
<td>7 (2-9)</td>
<td>0.001</td>
</tr>
<tr>
<td>Lower limbs VAS</td>
<td>10 (7-10)</td>
<td>7 (2-9)</td>
<td>0.001</td>
</tr>
<tr>
<td>Prevalent VAS</td>
<td>10 (7-10)</td>
<td>7.5 (0-9)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Baseline 12 months P Values

- Axial VAS: 10 (8-10), 5 (2-6), P<0.001
- Lower limbs VAS: 10 (7-10), 3 (0-7), P<0.001

Baseline 18 months P Values

- Axial VAS: 10 (8-10), 5 (2-6), P<0.001
- Lower limbs VAS: 10 (7-10), 3 (0-5), P<0.001
- Prevalent VAS: 10 (7-10), 3 (0-5), P<0.001

Baseline 24 months P Values

- Axial VAS: 10 (8-10), 5 (2-6), P<0.001
- Lower limbs VAS: 10 (7-10), 3 (0-5), P<0.001
- Prevalent VAS: 10 (7-10), 3 (0-7), P<0.001

© Under License of Creative Commons Attribution 3.0 License
Within the 22 patients implanted, 8 (36.36%) were subjected to the octet and 14 (63.63%) to the S-series (Lamitrode) procedure. Leads were connected through an extension cable to rechargeable IPGs and a few non rechargeable IPGs.

We performed the temporary implant 22 patients (100%) connecting the lead to an external pulse generator for a trial period of 21-90 days. Type and pattern of stimulation was continuous standard stimulation during trial period and therapy period. VAS values of patients were not 50% lower than baseline VAS values of patients in which trial electrode which removed after trial period.

The temporary implant was performed with the patient in the prone position under local anesthesia and deep sedation. Sedation was reduced after positioning the lead on the dural surface to evaluate pain coverage and acceptance of stimulation.

**Follow-up**

We analysed results after 6-12-18-24 months of stimulation and we compared the outcomes between onset VAS values and respectively 6-12-18-24 months VAS values.

The present analysis evaluates results of SCS therapy after 6-12-18-24 months from permanent implant in terms of:

1. Pain relief, pain coverage and presence of associated symptoms
2. Ongoing pharmacological or other conservative therapies
3. Adverse events and changes in stimulation settings
4. Hamilton’s scale for depression
5. Oswestry disability index (ODI)
6. Short form-36 (SF 36) health survey
7. Euro quol dimensions (EQ5D) score

EQ5D score evaluate health-related quality of life with a questionnaire focused on five points (mobility, self-care, usual activities, pain/discomfort, anxiety/depression).

**Statistical methods**

Descriptive statistics were reported as mean and standard deviation for normally distributed continuous variables, or median with 25-75 percentiles in case of skewed distribution. Normality was assessed by means of Shapiro-Walk test. Absolute and relative frequencies are reported for categorical variables.

Statistical comparisons of continuous variables were performed by paired-samples T test or non-parametric test (Wilcoxon rank-sum test) for normal and non-normal distributions, respectively.

In order to calculate the percentage of VAS improvement, difference between follow-up and base-line was divided by baseline value.

All two-tailed P value <0.05 was considered statistically significant.

SPSS 11.5 for Windows was used for statistical analysis.

**Results**

All patients were affected by neuropathic pain, mostly localized to one or both lower limbs, with radicular localization, and associated with low-back pain in several cases. In a few cases patients were suffering from isolated axial pain or other type of pain. The rate of patients who were suffering from prevalent lower-limb pain were 50%.

**Clinical results: After trial period**

Four patients had removal of temporary device after the trial period for the following reasons:
1. Non-responders, 2 patients
2. Infection 2 patients

IPGs removed 3 months after trial period in one patient and also 6 months after trial period in one patient.

Analyzing VAS score (prevalent, axial and lower limbs pain) compared between baseline and 6-12-18-24 months of stimulation. Reduction of VAS (after 6-12-18-24 months) reached

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Baseline</th>
<th>12 months</th>
<th>P values</th>
</tr>
</thead>
<tbody>
<tr>
<td>EQ5D Index</td>
<td>0.2 ± 0.18</td>
<td>0.76 ± 0.12</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>EQ5D VAS</td>
<td>4.2 ± 0.12</td>
<td>1.4 ± 0.22</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ODI</td>
<td>41.7 ± 9.87</td>
<td>17.6 ± 14.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SF-36 PCS</td>
<td>25.4 ± 9.3</td>
<td>40.4 ± 8.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SF-36 MCS</td>
<td>42.7 ± 9.4</td>
<td>40.1 ± 10.7</td>
<td>0.378</td>
</tr>
<tr>
<td>Baseline</td>
<td>24 months</td>
<td>P values</td>
<td></td>
</tr>
<tr>
<td>EQ5D Index</td>
<td>0.2 ± 0.18</td>
<td>0.72 ± 0.22</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>EQ5D VAS</td>
<td>4.2 ± 0.12</td>
<td>1.6 ± 0.33</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ODI</td>
<td>41.7 ± 9.87</td>
<td>14.9 ± 12.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SF-36 PCS</td>
<td>25.4 ± 9.3</td>
<td>42.4 ± 10.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SF-36 MCS</td>
<td>42.7 ± 9.4</td>
<td>38.3 ± 8.9</td>
<td>0.456</td>
</tr>
</tbody>
</table>

PCS: Physical Score; MCS: Mental Component Score
statistical significance in patients for lower limb pain and for prevalent pain (P<0.001). Reduction of axial pain VAS (after 12-18-24 months) could be reported as statistically significant in the patients (P<0.001), reduction of axial pain in 6 months only (p=0.001).

Considering quality of life improvement at 12-24 months, ODI, Physical Component score (PCS) of SF36 questionnaire and EQSD questionnaires significantly improved in patients (P<0.001, P<0.001), SF36 Mental Component Score (MCS) questionnaire did not significantly improve in patients (P=0.378, P=0.456) (Table 4).

Adverse events and causes of device removal

Nine complications occurred in 9 patients (45% of implanted subjects) and were grouped as technical (n=6) and clinical (n=3).

All clinical complications occurred in the patients and included one case of infection, one loss of efficacy. Six of technical complications occurred in the patients and included one connecting cable fractures, three early battery depletions, one lead dislocation and one lead fractures.

Six patients underwent revision surgery: One lead connection repositioning, two lead replacements and lead exploration, one lead fracture.

Six of the 22 patients (27.27%) were explanted after permanent SCS implant, we want to emphasize that only 2 (9.09%) patients were explanted due to infection.

Starting from initial population of 22 patients, only 4 patients (18.18%) decided not to have the permanent implant after the trial period, reporting poor efficacy of the SCS. One patients refused the permanent implant for personal reasons and one patient was explanted due to infection.

Complications and causes of explant

Starting from initial population of 22 patients, only 4 patients (18.18%) decided not to have the permanent implant after the trial period, reporting poor efficacy of the SCS. One patients refused the permanent implant for personal reasons and one patient was explanted due to infection.

Analyzing clinical outcomes in the 18 patients that underwent permanent SCS implant, we want to emphasize that only 2 (9.09%) patients were explanted because of loss of satisfaction or discomfort. In the literature we found a reduction of effectiveness rate 6% at 1 year [15] and 11% at 24 months [25].

Complications of SCS have been summarized in different classifications, and some authors define them as neurological, non-neurological and hardware related [8,25,35].

Some previous studies aimed at analyzing complications and cost-effectiveness reported an overall rate of SCS related complications of 35% [36] or 32% of device related complications [8]. In a review of 707 cases, the rate of hardware-related complications (including lead migrations, lead connection failure and lead break) was 38.1%, while the rate of documented infections was 4.5% with one case epidural infection [35]. One study about the 11 year experience with SCS reported an infection rate of 4.9% [37].

Our overall complications rate (27.27%) is comparable [34,38,39] that reported in the main literature (Table 5).

Conclusion

Our results enforce the evidence of efficacy of SCS therapy in terms of pain reduction, patient satisfaction and quality of life, according to previously published studies.
Table 5 Comparison of our analysis with literature (Studies in which VAS reduction > 50% was used as primary outcome).

<table>
<thead>
<tr>
<th>Study</th>
<th>Pain Aetiology</th>
<th>Patients, Total</th>
<th>Patients Implanted</th>
<th>Patients with Primary Outcomes at 12 Months</th>
<th>ODI Baseline</th>
<th>ODI 12 Months</th>
<th>SF36</th>
<th>Complication Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kupers et al. [26]</td>
<td>FBSS, CRPS neuropathic, PVD</td>
<td>700</td>
<td>52%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Van de cleft (1994)</td>
<td></td>
<td>116</td>
<td>84</td>
<td>54%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burchiel et al. [17]</td>
<td>FBSS</td>
<td>219 (6 centres)</td>
<td>182</td>
<td>55%</td>
<td>0.542 (SD0.14)</td>
<td>0.469 (SD0.2)</td>
<td></td>
<td>17%</td>
</tr>
<tr>
<td>Kumar et al. [2]</td>
<td>FBSS, CRPS, other neuropathic PVD</td>
<td>235</td>
<td>189</td>
<td>59%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Van Buyten et al. [32]</td>
<td>FBSS</td>
<td>254</td>
<td>217</td>
<td>68%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dario et al. [13]</td>
<td>FBSS</td>
<td>49</td>
<td></td>
<td>71%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>North et al. [28]</td>
<td>FBSS</td>
<td>24</td>
<td></td>
<td>47%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taylor [29]</td>
<td>FBSS, CRPS, other neuropathic</td>
<td>3313 (65 studies)</td>
<td>1992</td>
<td>62% (56-69%)</td>
<td></td>
<td></td>
<td></td>
<td>18%</td>
</tr>
<tr>
<td>Kumar et al. [8,9]</td>
<td>FBSS</td>
<td>52</td>
<td></td>
<td>58% (6 months); 48% (12 months)</td>
<td>52</td>
<td>44.9 (6 months)</td>
<td></td>
<td>45%</td>
</tr>
<tr>
<td>Turner et al. [31]</td>
<td>FBSS, CRPS, other neuropathic</td>
<td>51</td>
<td></td>
<td>15%</td>
<td></td>
<td></td>
<td></td>
<td>16%</td>
</tr>
<tr>
<td>Sears [24]</td>
<td>FBSS, CRPS</td>
<td>52</td>
<td></td>
<td>42.50%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slavin et al. [15]</td>
<td>FBSS, other neuropathic</td>
<td>334 (4 studies)</td>
<td>300 (2 out of 4 studies)</td>
<td>3 months: 75.4%, 12 months 76.3%</td>
<td></td>
<td></td>
<td></td>
<td>Improving: 3 months 77.9%, 75% at 1 year</td>
</tr>
<tr>
<td>Colombo [39]</td>
<td>FBSS, CRPS, Other neuropathic</td>
<td>122</td>
<td>106</td>
<td>63.8%</td>
<td>47.7 (SD19.0)</td>
<td>24.9 (SD19.0)</td>
<td></td>
<td>P&lt;0.001 14%</td>
</tr>
<tr>
<td>Our Analysis</td>
<td>FBSS, other neuropathic</td>
<td>22</td>
<td>18</td>
<td>12 months: 100% 24 months: 100%</td>
<td>42.7 (9.4)</td>
<td></td>
<td></td>
<td>P&lt;0.001 27.27%</td>
</tr>
</tbody>
</table>
References


